NPPA Publishes Revised MRPs for 543 Cancer Drug Brands, With Cuts of Up to 93% but Innovator Prices Unchanged
NPPA has released revised MRPs for 543 anti-cancer brands and packs under its 30% trade margin cap, effective 9 November, with generics and biosimilars cut by up to 93% while brands such as Avastin, Keytruda and nivolumab see no change.






